News | November 04, 2013

MitraClip Demonstrates Positive Results for Patients With Degenerative Mitral Regurgitation

Treatment provides clinical benefits for patients with debilitating mitral valve disease

heart valve repair clinical trial study abbott mitraclip TCT
November 4, 2013 — New trial data showed clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure and functional improvements for patients treated with the Abbott's first-in-class, catheter-based MitraClip therapy. The data was from patients with degenerative mitral regurgitation (MR) who are at prohibitive risk for mitral valve surgery. Findings were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013) in San Francisco and simultaneously published in the Journal of the American College of Cardiology.
 
The MitraClip device, which received U.S. Food and Drug Administration (FDA) approval, provides physicians with a breakthrough treatment option for patients suffering from MR. The MitraClip device is available in the United States for patients with significant symptomatic degenerative MR who are at prohibitive risk for mitral valve surgery.
 
"The results of this study show that, even for some of the most ill and debilitated patients, the MitraClip system is safe and results in good clinical outcomes," said D. Scott Lim, M.D., associate professor of cardiovascular medicine, University of Virginia Health System, Charlottesville, Va., and lead author of the publication. "These prohibitive-risk patients have had, until now, no approved therapies to improve the quality of their lives."
 
 
Data from 127 patients with degenerative MR at prohibitive surgical risk treated with the MitraClip device demonstrate:
  • Clinically meaningful changes to quality of life. Following MitraClip treatment, changes in SF-36 summary scales (a quality-of-life survey) were well above established thresholds showing minimum clinically important differences.
  • A reduction in rehospitalization for heart failure of 73 percent.
  • Functional improvements, with 76 percent of patients with baseline New York Heart Association (NYHA) Functional Class III improving to NYHA Functional Class I or II and 65 percent of patients with baseline NYHA Functional Class IV improving to NYHA Functional Class I or II.
  • Favorable ventricular remodeling, with left ventricular end-diastolic and end-systolic volume decreased significantly at one year compared with baseline.
  • A majority of patients discharged to home (87 percent) rather than to nursing care.
 
Ted Feldman, M.D., FSCAI, director, cardiac catheterization laboratory and The Mr. and Mrs. Charles R. Walgreen Chair in Interventional Cardiology, NorthShore University HealthSystem, Evanston, Ill., presented the findings.
 
Multiple trials published reports and registries of patients treated with the MitraClip device consistently demonstrate a positive safety profile, reduction in mitral regurgitation, improvement in symptoms and reduction in hospitalizations for heart failure even in some of the most ill and debilitated patients.
 
For more information: www.abbottvascular.com, www.onlinejacc.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init